Corcept Therapeutics has presented late-breaking data from its MOMENTUM trial at the 2026 American College of Cardiology Annual Scientific Session, reporting that hypercortisolism was identified in 27.3 percent of 1,086 patients screened with resistant hypertension across 50 United States sites. The finding, described as Featured Clinical Research at ACC 2026, extends a body of evidence the California-based biotech firm has assembled across two major prevalence trials and marks the largest US-based screening study ever conducted in this patient population.

What the 27 percent prevalence figure reveals about an underdiagnosed condition

The MOMENTUM result does not emerge in isolation. Corcept’s earlier CATALYST trial, which screened 1,057 patients with difficult-to-control type 2 diabetes, found hypercortisolism in 23.8 percent of that cohort. Taken together, the two trials form a consistent pattern: in patients whose cardiometabolic conditions resist standard-of-care treatment, elevated cortisol is present at rates that clinicians have historically not anticipated. The convergence of these figures across two distinct but overlapping patient populations adds weight to the argument that endogenous hypercortisolism is a systemic contributor to treatment-resistant disease, not an incidental finding confined to classical Cushing’s syndrome presentations.

The overlap between the two studies becomes more pronounced when patient profiles intersect. Among patients in MOMENTUM with haemoglobin A1c of 7.5 percent or higher who were taking three or more blood pressure medications, the hypercortisolism rate rose to 32.6 percent. The comparable figure in CATALYST, which applied a similar metabolic filter, was 36.6 percent. These subgroup findings suggest that clinicians dealing with patients who carry both uncontrolled diabetes and refractory hypertension are working with populations where cortisol excess may be present in roughly one in three cases. The clinical implications of that density are considerable and have not previously been incorporated into routine cardiological or diabetological workup protocols.

How the dexamethasone suppression test shapes the screening case

MOMENTUM used the one-milligram dexamethasone suppression test as its primary screening instrument. This is a well-established endocrinological tool, but its deployment at scale within a cardiology trial setting is less conventional. The test’s operational simplicity is central to the argument Corcept is making to the broader medical community: that identifying hypercortisolism in resistant hypertension does not require specialist infrastructure. A single standardised biochemical test administered at any of the 50 enrolling sites across the United States was sufficient to detect cortisol excess in more than a quarter of those screened.

The simplicity of the screening methodology is both a strength and a limitation of the trial design. On one side, a test that can be administered uniformly across a geographically diverse set of sites reduces variability and strengthens the generalisability of the prevalence estimate. On the other side, the dexamethasone suppression test produces false positives in certain clinical contexts, including patients on certain medications, those with obesity, and individuals with psychiatric comorbidities, all of which overlap substantially with the resistant hypertension population. MOMENTUM’s reported prevalence figures therefore need to be interpreted with an awareness that confirmation through additional testing, typically 24-hour urinary free cortisol measurement or late-night salivary cortisol, would be required before any clinical intervention could be justified.

Where Corcept’s commercial positioning intersects with the scientific narrative

Corcept has an established commercial footprint in cortisol modulation. Korlym, its mifepristone-based drug, has been on the market since 2012 for patients with endogenous Cushing’s syndrome and comorbid type 2 diabetes or glucose intolerance. In 2026, the company added Lifyorli to its portfolio, an FDA-approved selective glucocorticoid receptor antagonist indicated in combination with nab-paclitaxel for adults with platinum-resistant ovarian cancer. The MOMENTUM data, while framed as a prevalence and screening study rather than a treatment trial, positions Corcept to argue for expanded clinical recognition of hypercortisolism in settings where its existing and pipeline agents could theoretically be deployed.

Industry observers tracking the cortisol modulation space note that the commercial logic behind MOMENTUM is relatively transparent. A company that holds the leading approved therapy for Cushing’s syndrome and is developing pipeline candidates across solid tumours, ALS, and liver disease has a structural interest in demonstrating that the condition is more prevalent than clinicians currently recognise. That does not invalidate the data, but it does underline the importance of independent replication. MOMENTUM was conducted by Corcept, sponsored by Corcept, and its lead investigator serves as a paid consultant to the company. The steering committee structure and publication pathway will be closely scrutinised by guideline-setting bodies before any changes to routine screening recommendations are likely to follow.

Resistant hypertension as a gateway diagnosis for endocrine investigation

Resistant hypertension as defined by the American Heart Association criteria, specifically systolic blood pressure at or above 130 millimetres of mercury despite three or more antihypertensive agents including a diuretic, or four or more agents regardless of class, already carries a significant workup burden. Current guidelines direct clinicians to evaluate these patients for secondary causes of hypertension including primary aldosteronism, renal artery stenosis, and obstructive sleep apnoea. Hypercortisolism is acknowledged in secondary hypertension guidelines but is typically listed as a rarer aetiology and is not universally tested.

If the MOMENTUM prevalence figures hold up under independent scrutiny and are replicated in non-industry-funded cohorts, the argument for adding a standardised cortisol screen to the resistant hypertension workup becomes more difficult to dismiss. Cardiology and hypertension societies have historically deferred to endocrinology on hypercortisolism management, but a prevalence rate approaching 30 percent in a common and high-risk phenotype would make continued deferral harder to justify. The cardiovascular event risk associated with resistant hypertension, including elevated rates of stroke, myocardial infarction, heart failure, and renal damage, creates a compelling case for identifying and removing any reversible contributor.

What remains unresolved after the ACC 2026 presentation

MOMENTUM answers the prevalence question in this population with more precision than any prior study. What it does not address is whether identifying and treating hypercortisolism in resistant hypertension patients improves cardiovascular outcomes. The trial was designed and powered to determine how common the condition is, not to test whether intervention leads to blood pressure normalisation, reduced medication burden, or reduction in major adverse cardiovascular events. That gap is the most consequential limitation and the one most likely to determine whether this data translates into guideline change.

Regulatory watchers and clinical trialists will want to see interventional data before any treatment recommendation can be made. A trial that demonstrates improved blood pressure control or reduced antihypertensive polypharmacy following cortisol-targeted therapy in this population would be transformative. Without that evidence, MOMENTUM functions as an epidemiological signal, an important one, but insufficient on its own to change prescribing behaviour or generate reimbursement pressure on payers. Whether Corcept plans a follow-on interventional trial in the resistant hypertension population has not been disclosed, but the prevalence data would provide a straightforward justification for one.

The combined picture from MOMENTUM and CATALYST suggests that Corcept is systematically constructing an evidence base for broader hypercortisolism screening across cardiometabolic medicine. The two trials together have screened more than 2,100 patients across resistant hypertension and difficult-to-control diabetes and consistently found cortisol excess in roughly one in four. That body of work is substantive. The next phase of scientific development in this space will require independent trial sponsors, interventional designs, and outcome endpoints that regulators and payers can act on.

  American College of Cardiology, CATALYST, Corcept Therapeutics, cortisol, Cushing’s syndrome, Deepak Bhatt, dexamethasone suppression test, hypercortisolism, Korlym, Lifyorli, MOMENTUM, Mount Sinai, resistant hypertension